# NCT02598661 (NCT02598661)

> Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02598661
- Phase: PHASE2, PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Geron Corporation
- Conditions: Myelodysplastic Syndromes
- Interventions: Imetelstat Sodium; Placebo
- Enrollment: 289
- Primary outcome: Phase 2: Percentage of Participants Without Any Red Blood Cell (RBC) Transfusion During Any Consecutive 8-Weeks Period (All Participants)
- Primary outcome: Phase 2: Percentage of Participants Without Any RBC Transfusion During Any Consecutive 8-Weeks Period in Target Population
- Primary outcome: Phase 3: Percentage of Participants Without Any RBC Transfusion During Any Consecutive 8-Weeks Period

## Indexed commentary on NCT02598661 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 5

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct02598661